Global

‡ In these countries please contact our distributor

Smith & Nephew introduces PICO™ 14 sNPWT and presents new evidence to help improve outcomes in hard to heal wounds at EWMA conference

PICO 14 product image

4 June 2019

Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, is excited to introduce the new PICO 14 Single Use Negative Pressure Wound Therapy System (sNPWT) which has a pump duration of up to 14 days,1 an enhanced pump to aid use in large wounds with less user intervention,2* and is aimed for use in deep wounds, such as 7 centimetres deep.3

The new addition to the PICO family, PICO 14 sNPWT, will be presented at the European Wound Management Association (EWMA) conference to be held in Gothenburg, Sweden 5 – 7 June 2019, together with new PICO evidence on managing hard-to heal wounds and mechanism of action.

Earlier intervention with PICO sNPWT in hard-to-heal wounds has been observed to improve the proportion of wounds healed.4† The PICO sNPWT has also been shown to significantly improve healing trajectory with an average wound reduction of 9.6% more compared to standard dressings;4** and 30% greater area and depth reduction compared to traditional negative pressure (tNPWT) 5. The PICO sNPWT has also shown to reduce use of healthcare resources compared to standard of care4, 6§ and tNPWT5.

The unique PICO sNPWT dressing includes AIRLOCK™ Technology for uniform and consistent delivery of therapeutic NPWT across a wound and the surrounding zone of injury.7 By minimising the need for fillers and reducing dressing change frequency compared with traditional NPWT5, PICO sNPWT helps healing to progress undisturbed, contributing to faster time to healing, improved quality and distribution of granulation tissue and more consistent re-epithelialisation.8

PICO™ sNPWT has a strong evidence base with 103 published papers of which 20 are published randomised controlled trials (RCTs) and 65 are unique clinical studies.10

In addition to introducing PICO 14 sNPWT, Smith & Nephew is hosting two symposia at the EWMA conference. “Achieve better outcomes for your hard-to-heal wounds with PICO™ Single Use Negative Pressure Wound Therapy System” is chaired by Professor Christina Lindholm, Sweden with presentation by amongst others Jane Hampton, Denmark.

The symposium “Achieving consistency in practice through an evolved T.I.M.E. 9 framework” will see Prof. Zena Moore, Ireland, Dr. Gregory Schultz, US and Terry Swanson, Australia present a new T.I.M.E clinical decision support tool (CDST) to help achieve reduction in practice variation, and with examples of implementing T.I.M.E. CDST in practice.

“We are proud to showcase the new PICO 14 at this year’s EWMA, adding to our complete leading portfolio that can help address every aspect of T.I.M.E. supporting the broad range of clinical needs our customers face daily.“ said Paolo Di Vincenzo, Smith & Nephew’s Senior Vice President Global Marketing, Advanced Wound Management.“

The full Smith & Nephew programme can be found at www.smith-nephew.com/EWMA2019

PICO 14 completed the CE mark process on 18 April 2019. Not available in the US. Read more about PICO 14 sNPWT at www.smith-nephew.com/pico14

 

Enquiries

Media

 

Dave Snyder

+1 (978) 749-1440

Smith & Nephew

 

* compared to previous versions

† p=0.001; 52 wounds; 0-3 vs 12+ months starting wound duration

** p=0.001; 52 wounds

‡ p<0.001 for area and p=0.014for depth; n=161; Intention to treat analysis, at 12 weeks, combined population on a VLU and DFU study.

§ Reduction per patient of 1-2 outpatient visits over 12-week treatment period and 1-3 home visits per week

‖ p=0.028 for faster, p=0.025 granulation, p<0.001 re-epithelialisation.

References

  1. Smith & Nephew December 2018. PICO 14 Service Life Testing: 14 Day Device Lifespan. Internal Report. RD/18/132.
  2.  Smith & Nephew. Research & Development Report. PICO 14 and PICO 7 Initial Pump Down and Maintenance Pump Down Time Outs RD/19/084
  3. Smith & Nephew 2018. The review of evidence supporting the use of PICO in wounds ≥2cmin depth. Internal report EO AWM. PCS230.001 v2
  4. Dowsett C, Hampton J, Myers D, Styche T. Use of PICO to improve clinical and economic outcomes in hard-to-heal wounds. Wounds International. 2017;8, p53–58.
  5. Kirsner R, Dove C, Reyzelman A, Vayser D, Jaimes H. A Prospective, Randomized, Controlled Clinical Trial on the Efficacy of a Single‐use Negative Pressure Wound Therapy System, Compared to Traditional Negative Pressure Wound Therapy in the Treatment of Chronic Ulcers of the Lower Extremities. Journal of woundcare and regeneration. May 2019. https://doi.org/10.1111/wrr.12727
  6. Sharpe A, Myers D, Searle R. Using single use negative pressure wound therapy for patients with complicated diabetic foot ulcers: an economic perspective. Wounds UK. 2018; 14:80-84. Available at: Wounds UK.
  7. Smith & Nephew October 2017. Project Opal PICO 7 System Stability Testing, Initial Time Point. Internal Report. DS/17/253/R.
  8. Brownhill R, Bell A, Hart J, Webster I & Huddleston E. Pre-clinical Assessment of a No-canister, Ultra-portable, Single use Negative Pressure Wound Therapy (sNPWT) System* in a Porcine Model of Wound Healing: Unlocking its Mode of Action. Poster presented at the Advanced Wound Care (SAWC) Conference, 7-11 May 2019, San Antonio, Texas.
  9. Moore Z, Dowsett C, Smith G, et al. TIME CDST: an updated tool to address the current challenges in wound care. J Wound Care. 2019;28(3):154-161.
  10. Smith & Nephew. Analysis by Dr Vicki Strugala. January 2019 

About Smith & Nephew

Smith & Nephew is a portfolio medical technology business that exists to restore people’s bodies, and their self-belief. Smith & Nephew has leadership positions in Orthopaedics, Advanced Wound Management and Sports Medicine, more than 16,000 employees and a presence in more than 100 countries. Annual sales in 2018 were $4.9 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN). For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com and follow us on TwitterLinkedIn or Facebook.

To learn more about how we can help you get CLOSER TO ZERO™ delay in wound healing, please visit www.closertozero.com

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

Trademark of Smith & Nephew.  Certain marks registered US Patent and Trademark Office.

AWM-AWD-19263